Document:

EX-10.16

 Exhibit 10.16 

DIRECTOR NOMINATION AGREEMENT 

THIS DIRECTOR NOMINATION AGREEMENT (this “Agreement”) is made and entered into as of June 18th, 2021, by and among
LegalZoom.com, Inc., a Delaware corporation (the “Company”), LucasZoom, LLC, a Delaware limited liability company (together with its affiliated investment entities, “Permira”), FPLZ I, L.P., a Delaware limited
partnership (“FPLZ I”), and FPLZ II, L.P. (together with FPLZ I and their affiliated investment entities, “Francisco” and together with Permira, the “Lead Sponsors”). This Agreement shall become
effective (the “Effective Date”) upon the closing of the Company’s initial public offering (the “IPO”) of shares of its common stock, par value $0.001 per share (the “Common Stock”); provided,
however, that this Agreement shall expire and be of no further force or effect if the IPO does not occur on or prior to December 31, 2021. 

WHEREAS, the Lead Sponsors and the Company are contemplating causing the Company to effect the IPO; 

WHEREAS, the Lead Sponsors currently have the authority to appoint certain members of the board of directors of the Company; 

WHEREAS, in consideration of the Lead Sponsors agreeing to undertake the IPO, the Company has agreed to permit the Lead Sponsors to designate
persons for nomination for election to the board of directors of the Company (the “Board”) following the Effective Date on the terms and conditions set forth herein; 

NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, each of the parties to this Agreement agrees as follows: 
 1. Board Nomination Rights.

 (a) From the Effective Date, (A) each Lead Sponsor shall have the right, but not the obligation, to nominate to the Board a number
of designees equal to at least: (i) two (2) Directors (as defined below), so long as such Lead Sponsor continuously from the time of the IPO Beneficially Owns shares of Common Stock representing at least 50% of the shares of Common Stock owned
by such Lead Sponsor immediately following the IPO, and (ii) one (1) Director, in the event that such continuously from the time of the IPO Lead Sponsor Beneficially Owns shares of Common Stock representing at least 25% but less than 50% of the
shares of Common Stock owned by such Lead Sponsor immediately following the IPO. 
 (b) In the event that any Lead Sponsor has nominated
less than the total number of designees that such Lead Sponsor shall be entitled to nominate pursuant to Section 1(a), such Lead Sponsor shall have the right, at any time, to nominate such additional designees to which it
is entitled, in which case, the Company shall take, and shall use commercially reasonable efforts to cause the Directors to take, all necessary corporate action, to the fullest extent permitted by applicable law (including with respect to fiduciary
duties under Delaware law), to (x) enable such Lead Sponsor to nominate and effect the election or appointment of such additional individuals, whether by increasing the size of the Board or otherwise, and (y) to designate such additional
individuals nominated by such Lead Sponsor to fill such newly created vacancies or to fill any other existing vacancies. 

 (c) The Company shall pay all reasonable out-of-pocket expenses incurred by any person nominated by a Lead Director hereunder (a “Nominee”) in connection with the performance of his or her duties as a director and in connection with
his or her attendance at any meeting of the Board. 
 (d) “Beneficially Own” shall mean that a specified person has or
shares the right, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, to vote shares of capital stock of the Company. “Affiliate” of any person shall mean any other person controlled
by, controlling or under common control with such person; where “control” (including, with its correlative meanings, “controlling,” “controlled by” and “under common control with”)
means possession, directly or indirectly, of power to direct or cause the direction of management or policies (whether through ownership of securities, by contract or otherwise). 

(e) “Director” means any member of the Board. 

(f) In the event that any Nominee shall cease to serve for any reason, the Lead Sponsor that nominated such Nominee shall be entitled to
designate such person’s successor in accordance with this Agreement (provided that at the time such Nominee ceases to serve, such Lead Sponsor’s Beneficial Ownership of Common Stock continues to enable the Lead Sponsor to designate such
replacement Nominee) and the Company shall use commercially reasonable efforts to cause the Board to the fullest extent provided by applicable law (including the Directors’ fiduciary duties under Delaware law) to promptly fill the vacancy with
such successor Nominee; it being understood that any such designee shall serve the remainder of the term of the director whom such designee replaces. 

(g) If a Nominee is not appointed or elected to the Board because of such person’s death, disability, disqualification, withdrawal as a
nominee or for other reason is unavailable or unable to serve on the Board, the applicable Lead Sponsor shall be entitled to designate promptly another nominee and the director position for which the original Nominee was nominated shall not be
filled pending such designation (provided that at the time of death, disability, disqualification, withdrawal or occurrence of the other reason the Nominee is not appointed or elected, such lead Sponsor’s Beneficial Ownership of Common Stock
continues to enable the Lead Sponsor to designate a replacement Nominee). 
 (h) So long as a Lead Sponsor has the right to nominate at
least one Nominee under Section 1(a) or any such Nominee is serving on the Board, the Company shall maintain in effect at all times directors and officers indemnity insurance coverage reasonably satisfactory to the Board, and the Company’s
Amended and Restated Certificate of Incorporation and Bylaws (each as may be further amended, supplemented or waived in accordance with its terms) shall at all times provide for indemnification, exculpation and advancement of expenses to the fullest
extent permitted under applicable law. 

  
 2 

 (i) At any time that a Lead Sponsor shall have any nomination rights under
Section 1, the Company shall not take any action, including making or recommending any amendment to Company’s Amended and Restated Certificate of Incorporation or Bylaws (each as may be further amended, supplemented or
waived in accordance with its terms) that could reasonably be expected to adversely affect a Lead Sponsor’s rights under this Agreement, in each case without the prior written consent of the adversely affected Lead Sponsor. 

(j) Notwithstanding anything in this Agreement to the contrary, a Lead Sponsor may not nominate or designate any person unless he or she would
qualify as “independent” under applicable stock exchange listing standards, unless otherwise approved by the Board. 
 2.
Company Obligations. The Company agrees that prior to the date that each Lead Sponsor and its Affiliates cease to Beneficially Own shares of Common Stock that would allow them to nominate Directors under Section 1(a) hereof, it will use
commercially reasonable efforts to cause the Board, to the fullest extent permitted by law (including the Directors’ fiduciary duties under Delaware law), to include (i) each Nominee in the Board’s slate of nominees to the
stockholders (the “Board’s Slate”) for each election of directors; and (ii) each Nominee in the proxy statement prepared by management of the Company in connection with soliciting proxies for every meeting of the
stockholders of the Company called with respect to the election of members of the Board (each, a “Director Election Proxy Statement”), and at every adjournment or postponement thereof. Each Lead Sponsor will promptly report to the
Company after such Lead Sponsor ceases to Beneficially Own shares of Common Stock that would allow such Lead Sponsor to nominate a director under Section 1(a) hereof, such that Company is informed of when this obligation terminates. The
calculation of the number of Nominees that each Lead Sponsor is entitled to nominate to the Board’s Slate for any election of directors shall be based on the outstanding Common Stock then Beneficially Owned by each Lead Sponsor immediately
prior to the mailing to stockholders of the Director Election Proxy Statement relating to such election (or, if earlier, the filing of the definitive Director Election Proxy Statement with the U.S. Securities and Exchange Commission). Unless a Lead
Sponsor notifies the Company otherwise prior to the mailing to stockholders of the Director Election Proxy Statement relating to an election of directors (or, if earlier, the filing of the definitive Director Election Proxy Statement with the U.S.
Securities and Exchange Commission), the Nominees for such election shall be presumed to be the same Nominees currently serving on the Board, and no further action shall be required of any Lead Sponsor for the Board to include such Nominees on the
Board’s Slate; provided, that, in the event a Lead Sponsor is no longer entitled to nominate the full number of Nominees then serving on the Board, such Lead Sponsor shall provide advance written notice to the Company of the currently serving
Nominee(s) who shall be excluded from the Board Slate, and of any other changes to the list of Nominees. If a Lead Sponsor fails to provide such notice prior to the mailing to stockholders of the Director Election Proxy Statement relating to such
election (or, if earlier, the filing of the definitive Director Election Proxy Statement with the U.S. Securities and Exchange Commission), a majority of the independent directors then serving on the Board shall determine which of the Nominees of
such Lead Sponsor then serving on the Board will be included in the Board’s Slate. The Company agrees to provide written notice of the preparation of a Director Election Proxy Statement to the Lead Sponsors at least 20 business days, but no
more than 80 business days, prior to the earlier of the mailing and the filing date of any Director Election Proxy Statement. 

  
 3 

 3. Amendment and Waiver. Any provision of this Agreement may be amended or waived if,
but only if, such amendment or waiver is in writing and is signed, in the case of an amendment, by the Company and each Lead Sponsor (for so long as such Lead Sponsor has the right to designate at least one Nominee hereunder), or in the case of a
waiver, by the party against whom the waiver is to be effective. No failure or delay by any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any
other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by law. The Lead Sponsors shall not be
obligated to nominate all (or any) of the Nominees it is entitled to nominate pursuant to this Agreement for any election of directors but the failure to do so shall not constitute a waiver of its rights hereunder with respect to future elections.
The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by law. 
 4. Benefit of
Parties. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective permitted successors and assigns. Notwithstanding the foregoing, the Company may not assign any of its rights or obligations
hereunder without the prior written consent of each Lead Sponsor. Except as otherwise expressly provided in Section 6, nothing herein contained shall confer or is intended to confer on any third party or entity that is not
a party to this Agreement any rights under this Agreement. 
 5. Assignment. A Lead Sponsor may not assign any of its rights
hereunder. 
 6. Headings. Headings are for ease of reference only and shall not form a part of this Agreement. 

7. Governing Law. This Agreement shall be construed in accordance with and governed by the law of the State of Delaware without giving
effect to the principles of conflicts of laws thereof. 
 8. Jurisdiction. Any suit, action or proceeding seeking to enforce any
provision of, or based on any matter arising out of or in connection with, this Agreement may be brought against any of the parties in any federal court located in the State of Delaware or any Delaware state court, and each of the parties hereby
consents to the exclusive jurisdiction of such court (and of the appropriate appellate courts) in any such suit, action or proceeding and waives any objection to venue laid therein. Process in any such suit, action or proceeding may be served on any
party anywhere in the world, whether within or without the jurisdiction of any such court. Without limiting the foregoing, each of the parties agrees that service of process upon such party at the address referred to in
Section 16, together with written notice of such service to such party, shall be deemed effective service of process upon such party. 

9. WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL
PROCEEDING ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT. 

  
 4 

 10. Entire Agreement. This Agreement constitutes the entire agreement among the
parties with respect to the subject matter hereof and supersedes all prior agreements, understandings and negotiations, both written and oral among the parties with respect to the subject matter hereof. 

11. Counterparts; Effectiveness. This Agreement may be signed in any number of counterparts, each of which shall be deemed an original.
This Agreement shall become effective when each party shall have received a counterpart hereof signed by each of the other parties. An executed copy or counterpart hereof delivered by facsimile shall be deemed an original instrument. 

12. Severability. If any provision of this Agreement or the application thereof to any person or circumstance shall be invalid or
unenforceable to any extent, the remainder of this Agreement and the application of such provisions to other persons or circumstances shall not be affected thereby and shall be enforced to the greatest extent permitted by law. 

13. Further Assurances. Each of the parties hereto shall execute and deliver such further instruments and do such further acts and
things as may be required to carry out the intent and purpose of this Agreement. 
 14. Specific Performance. Each of the parties
hereto agree that irreparable damage would occur if any provision of this Agreement were not performed in accordance with the terms hereof and that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement
or to enforce specifically the performance of the terms and provisions hereof in any federal or state court located in the State of Delaware, in addition to any other remedy to which they are entitled at law or in equity. 

15. Notices. All notices, requests and other communications to any party or to the Company pursuant to this Agreement shall be in
writing (including email or similar writing) and shall be given, 
 If to the Company: 

Legalzoom.com, Inc. 
 101 North
Brand Boulevard 
 11th Floor, Glendale, CA 91203 

Attention: Chief Executive Officer. 

With a copy to (which shall not constitute notice): 

Cooley LLP 
 1333 2nd Street, Suite 400 
 Santa Monica, CA 90401 

Attention: C. Thomas Hopkins 

Email: thopkins@cooley.com 

  
 5 

 If to any member of Francisco or any of its Nominees: 

Francisco Partners 
 One Letterman
Drive 
 Building C—Suite 410 

San Francisco, CA 94129 

Attention: Christine Wang 
 Email:
christine@franciscopartners.com 
 With a copy to (which shall not constitute notice): 

Paul Hastings, LLP 
 101
California Street, 48th Floor 
 San Francisco, CA 94111 

Attention: Michael J. Kennedy 

Email: mikekennedy@paulhastings.com 

If to Permira or any of its Nominees: 

c/o Permira Advisers LLC 
 3000
Sand Hill Road, Building 1 
 Menlo Park, CA 94025 

Attention: Legal Department 
 E-mail: Justin.Herridge@permira.com 
 With a copy to (which shall not constitute notice): 

Fried, Frank, Harris, Shriver & Jacobson LLP 

801 17th Street, NW 

Washington, DC 20015 
 Attention:
Brian Mangino 
 Email: Brian.Mangino@friedfrank.com 

or to such other address or telecopier number as such party or the Company may hereafter specify for the purpose by notice to the other parties and the
Company. Each such notice, request or other communication shall be effective when delivered at the address specified in this Section 16 during regular business hours. 

*        *        *       
 *        * 

  
 6 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the date first above
written. 
  

			
	LEGALZOOM.COM, INC.
		
	By:	 	/s/ Dan Wernikoff
	Name:	 	Dan Wernikoff
	Title:	 	Chief Executive Officer
	
	FPLZ I, L.P.
		
	By:	 	Francisco Partners GP V, L.P., its General Partner
		
	By:	 	Francisco Partners GP V Management, LLC, its General Partner
		
	By:	 	/s/ Tom Ludwig
	Name:	 	Tom Ludwig
	Title:	 	Director
	
	FPLZ II, L.P.
		
	By:	 	Francisco Partners GP V, L.P., its General Partner
		
	By:	 	Francisco Partners GP V Management, LLC, its General Partner
		
	By:	 	/s/ Tom Ludwig
	Name:	 	Tom Ludwig
	Title:	 	Director
	
	LUCASZOOM, LLC
		
	By:	 	/s/ Dipan Patel
	Name:	 	Dipan Patel
	Title:	 	VP and TreasurerEX-10.17

 Exhibit 10.17 

Execution Version 

COMMON STOCK PURCHASE AGREEMENT 

This Common Stock Purchase Agreement (“Agreement”) is made as of June 18, 2021 (the “Effective Date”), by
and among LegalZoom.com, Inc., a Delaware corporation (the “Company”), and the investors listed on Schedule A hereto (each, an “Investor” and collectively, the “Investors”). 

RECITALS 

A. The Investors desire to purchase from the Company, and the Company desires to sell and issue to the Investors, in the aggregate,
$90.0 million of the common stock, par value $0.001 per share, of the Company (the “Common Stock”), in a private placement that shall take place concurrently with the Company’s initial public offering of Common Stock (the
“IPO”) on the terms and subject to the conditions set forth in this Agreement (the “Financing”). 
 B.
The parties hereto have executed this Agreement on the Effective Date, which is prior to the effectiveness of the registration statement on Form S-1 filed by the Company with the Securities and Exchange
Commission (the “SEC”) for the IPO. 
 C. The closing of the Financing shall take place concurrently with the
closing of the IPO (such time, the “IPO Closing Time”) and at the price per share equal to the initial public offering price per share that the Common Stock is sold to the public in the IPO (before any underwriting discounts or
commissions) (the “IPO Price”), as set forth on the cover of the final prospectus filed with the SEC. 
 D. In order
to effect the IPO, the Company shall enter into an Underwriting Agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Barclays Capital Inc., as representatives of the several
underwriters named therein (the “Underwriters”). 
 AGREEMENT 

The parties agree as follows: 
  

	1.	 Purchase and Sale of Stock. 

1.1 Sale and Issuance of Stock. The Company agrees to issue and sell to the Investors, and the Investors agree to purchase from the
Company, in the aggregate, $90.0 million of Common Stock (the “Investment Amount”) at the IPO Price pursuant to a private placement exempt from registration under the Securities Act of 1933, as amended (the “Securities
Act”), in accordance with Rule 506 of Regulation D promulgated under the Securities Act. The number of shares of Common Stock to be sold by the Company and purchased by the Investors hereunder (the “Shares”) shall equal the
number of shares determined by dividing the Investment Amount by the IPO Price (rounded down to the nearest whole share). Payment of the purchase price (which shall be equal to the total number of Shares to be purchased by the Investors, as
calculated pursuant to the immediately preceding sentence, multiplied by the IPO Price) for the Shares (the “Purchase Price”) shall be made at the Closing (as defined below) by wire transfer of immediately available funds to the
account specified in writing by the Company to the Investors, subject to the satisfaction of the conditions set forth in this Agreement. Payment of the Purchase Price for the Shares shall be made against delivery to the Investors of the Shares,
which Shares shall be uncertificated and shall be registered in the name of the applicable Investor on the books of the Company by the Company’s transfer agent. No later than two days prior to the Closing, the Investors shall deliver to the
Company an updated Schedule A, setting forth the number of Shares to be purchased by each Investor and the corresponding portion of the Purchase Price to be paid by each such Investor in accordance with the terms of this Agreement. 

 1.2 Closing. The closing of the sale and purchase of the Shares (the
“Closing”) will take place remotely via the exchange of documents and signatures after the satisfaction or waiver of each of the conditions set forth in Section 4 and Section 5
(other than those conditions that by their nature are to be satisfied at the Closing, but subject to the fulfillment or waiver of those conditions). 
  

	2.	 Representations and Warranties of the Company. 

The Company hereby represents and warrants to the Investors that the following representations are true and correct as of the date hereof and
as of the Closing (except to the extent any such representations and warranties expressly relate to an earlier date, in which case such representations and warranties are true and correct as of such earlier date). 

2.1 Organization, Valid Existence and Qualification. The Company is a corporation duly organized and validly existing under the laws of
the State of Delaware and has all requisite corporate power and authority to carry on its business as currently conducted. The Company is duly qualified to transact business as a foreign corporation in each jurisdiction in which it conducts its
business, except where failure to be so qualified could not reasonably be expected to result, either individually or in the aggregate, in a material adverse effect on the Company’s financial condition, business or operations. 

2.2 Registration Statement. The Registration Statement and any prospectus contained therein will not, as of the filing date of such
Registration Statement, contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made,
not misleading. “Registration Statement” means the registration statement on Form S-1, including any prospectus filed pursuant to Rule 424 under the Securities Act, and any free writing
prospectuses, relating to the IPO. 
 2.3 Authorization. All corporate action on the part of the Company, its officers, directors and
stockholders necessary for the authorization, execution and delivery of this Agreement, the performance of all obligations of the Company hereunder, and the authorization, issuance, sale and delivery of the Shares, has been taken or will be taken
prior to the Closing, and this Agreement constitutes the valid and legally binding obligation of the Company, enforceable in accordance with its terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and
other laws of general application affecting enforcement of creditors’ rights generally, and (b) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies. 

2.4 Valid Issuance of Shares. The Shares that are being purchased by the Investors hereunder, when issued, sold and delivered in
accordance with the terms of this Agreement for the consideration expressed herein, will be duly and validly issued, fully paid, and nonassessable, and will be transferred to the Investors free of liens, encumbrances and restrictions on transfer
other than (a) restrictions on transfer under this Agreement and under applicable state and federal securities laws, (b) restrictions on transfer under the lock-up agreement entered into by the
Investors for the benefit of the Underwriters in the IPO and (c) any liens, encumbrances or restrictions on transfer that are created or imposed by the Investors. Subject in part to the truth and accuracy of the Investors’ representations
set forth in Section 3 of this Agreement, the offer, sale and issuance of the Shares as contemplated by this Agreement are exempt from the registration requirements of applicable state and federal securities laws. 

2.5 Non-Contravention. No consent, approval, order or authorization of, or registration,
qualification, designation, declaration or filing with, any federal, state or local governmental authority on the part of the Company is required in connection with the consummation of the sale and issuance of Shares contemplated by this Agreement,
except for the filing of notices of the sale of Shares pursuant to Regulation D promulgated under the Securities Act and applicable state securities laws. The execution, delivery and performance of this Agreement and the consummation of the
transactions contemplated hereby will not result in any such violation or constitute, with or 

  
 2 

 
without the passage of time and giving of notice, either (a) a default in any material respect of any such instrument, judgment, order, writ or decree, or (b) an event that results in
the creation of any lien, charge or encumbrance upon any assets of the Company or the suspension, revocation, impairment, forfeiture, or nonrenewal of any material permit, license, authorization or approval applicable to the Company, in each case,
which could reasonably be expected to result, either individually or in the aggregate, in a material adverse effect on the Company’s financial condition, business or operations. 

 

	3.	 Representations and Warranties of the Investors. 

Each Investor hereby represents and warrants to the Company that the following representations are true and correct as of the date hereof and
as of the Closing (except to the extent any such representations and warranties expressly relate to an earlier date, in which case such representations and warranties are true and correct as of such earlier date). 

3.1 Authorization. The Investor has all requisite power and authority to enter into this Agreement and this Agreement constitutes its
valid and legally binding obligations, enforceable in accordance with its terms except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general application affecting enforcement of
creditors’ rights generally, and (b) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies. 

3.2 Purchase Entirely for Own Account. This Agreement is made with the Investor in reliance upon the Investor’s representations to
the Company, which by the Investor’s execution of this Agreement the Investor hereby confirms, that the Shares acquired by the Investor hereunder will be acquired for investment for the Investor’s own account, not as a nominee or agent,
and not with a view to the resale or distribution of any part thereof, and that the Investor has no present intention of selling, granting any participation in, or otherwise distributing the same, except as permitted by applicable federal or state
securities laws. By executing this Agreement, the Investor further represents that the Investor does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participation rights to such person or to
any third person, with respect to any of the Shares. 
 3.3 No Solicitation. At no time was the Investor presented with or solicited
by any publicly issued or circulated newspaper, mail, radio, television or other form of general advertising or solicitation in connection with the offer, sale and purchase of the Shares. 

3.4 Access to Information. The Investor has received or has had access to all the information it considers necessary or appropriate to
make an informed investment decision with respect to the Shares to be purchased by the Investor under this Agreement. The Investor further has had an opportunity to ask questions and receive answers from the Company regarding the terms and
conditions of the offering of the Shares. The foregoing, however, does not in any way limit or modify the representations and warranties made by the Company in Section 2. 

3.5 Investment Experience. The Investor understands that the purchase of the Shares involves substantial risk. The Investor has
experience as an investor in securities of companies in the development stage and acknowledges that the Investor is able to fend for itself, can bear the economic risk of the Investor’s investment in the Shares, including a complete loss of the
investment, and has such knowledge and experience in financial or business matters that the Investor is capable of evaluating the merits and risks of this investment in the Shares and protecting its own interests in connection with this investment.
The Investor represents that the office in which its investment decision was made is located at the address set forth in Section 6.7. 

  
 3 

 3.6 Accredited Investor. The Investor understands the term “accredited
investor” within the meaning of Rule 501 of Regulation D promulgated under the Securities Act and is an “accredited investor” for the purposes of acquiring the Shares to be purchased by the Investor under this Agreement. 

3.7 Restricted Securities. The Investor understands that the Shares are characterized as “restricted securities” under the
Securities Act inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under the Securities Act and applicable regulations thereunder such securities may be resold without registration under the
Securities Act only in certain limited circumstances. The Investor represents that the Investor is familiar with Rule 144 of the Securities Act, as presently in effect, and understands the resale limitations imposed thereby and by the Securities
Act. The Investor understands that the Company is under no obligation to register any of the securities sold hereunder. 
 3.8
Legends. The Investor understands that the book-entry account evidencing the Shares may bear one or all of the following legends (or substantially similar legends): 

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE
SECURITIES LAWS OF APPLICABLE STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR
EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. 

THE SECURITIES REPRESENTED HEREBY ARE SUBJECT TO A LOCK-UP AGREEMENT EXECUTED BY THE ORIGINAL HOLDER OF
THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. AS A RESULT OF SUCH AGREEMENT, THESE SHARES MAY NOT BE TRADED FOR A PERIOD OF TIME AFTER THE DATE OF THE UNDERWRITING AGREEMENT EXECUTED IN CONNECTION WITH THE
INITIAL PUBLIC OFFERING OF THE COMMON STOCK OF THE ISSUER HEREOF. SUCH RESTRICTION IS BINDING ON TRANSFEREES OF THESE SHARES. 
 3.9 No
Brokers. The Investor has not incurred, and will not incur in connection with the purchase of the Shares, any brokerage or finders’ fees, or agents’ commissions or similar liabilities. 

 

	4.	 Conditions to the Investors’ Obligations at Closing. 

The obligations of the Investors to consummate the Closing are subject to the fulfillment or waiver, on or by the Closing, of each of the
following conditions, which waiver may be given by written communication to the Company: 
 4.1 Representations and Warranties. Each
of the representations and warranties of the Company contained in Section 2 (a) that are not qualified as to materiality or material adverse effect shall be true and accurate in all material respects on and as of the
Closing with the same force and effect as if they had been made at the Closing, except for those representations and warranties that address matters only as of a particular date (which shall remain true and correct as of such particular date), and
(b) that are qualified as to materiality or material adverse effect shall be true and accurate in all respects on and as of the Closing with the same force and effect as if they had been made at the Closing, except for those representations and
warranties that address matters only as of a particular date (which shall remain true and correct as of such particular date). 

  
 4 

 4.2 Performance. The Company shall have performed and complied in all material
respects with all agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before the Closing and shall have obtained all approvals, consents and qualifications necessary to
complete the purchase and sale described herein. 
 4.3 IPO. The Registration Statement shall have been declared effective by the SEC.
The Underwriters shall have purchased, concurrently with the purchase of the Shares by the Investors hereunder, the Firm Shares (as defined in the Underwriting Agreement) at the IPO Price (less any underwriting discounts or commissions). 

4.4 Qualifications. All authorizations, approvals, waiting period expirations or terminations, or permits, if any, of any governmental
authority or regulatory body of the United States or of any state that are required in connection with the lawful issuance and sale of the Shares pursuant to this Agreement shall be duly obtained and effective as of the Closing, other than
(a) the filing pursuant to Regulation D, promulgated under the Securities Act, and (b) the filings required by applicable state “blue sky” securities laws, rules and regulations. 

4.5 Absence of Injunctions and Decrees. During the period from the Effective Date to immediately prior to the Closing, no governmental
authority of competent jurisdiction shall have enacted, issued, promulgated, enforced or entered any decision, injunction, decree, ruling, law or order enjoining or otherwise prohibiting or making illegal the consummation of the transactions
contemplated at the Closing. 
  

	5.	 Conditions to the Company’s Obligations at Closing. 

The obligations of the Company to the Investors to consummate the Closing are subject to the fulfillment, on or by the Closing, of each of the
following conditions, which waiver may be given by written communication to the Investors: 
 5.1 Representations and Warranties. The
representations and warranties of the Investors contained in Section 3 shall be true and accurate in all material respects on and as of the Closing with the same force and effect as if they had been made at the Closing.

 5.2 Performance. The Investors shall have performed and complied in all material respects with all agreements, obligations and
conditions contained in this Agreement that are required to be performed or complied with by the Investors on or before the Closing and shall have obtained all approvals, consents and qualifications necessary to complete the purchase and sale
described herein. 
 5.3 IPO. The Registration Statement shall have been declared effective by the SEC. The Underwriters shall have
purchased the Firm Shares at the IPO Price (less any underwriting discounts or commissions). 
 5.4 IPO Lockup. The Investors shall
have signed a lockup agreement in the form previously agreed upon by the Investors and the Underwriters. The Shares shall be subject to the terms of the lockup agreement. 

5.5 Absence of Injunctions and Decrees. During the period from the Effective Date to immediately prior to the Closing, no governmental
authority of competent jurisdiction shall have enacted, issued, promulgated, enforced or entered any decision, injunction, decree, ruling, law or order enjoining or otherwise prohibiting or making illegal the consummation of the transactions
contemplated at the Closing. 

  
 5 

	6.	 MISCELLANEOUS. 

6.1 Publicity. No party shall issue any press release or make any other public announcement, including any website posting or social
media post, that includes the name or any logo or brand name of any party, or discloses the terms of this Agreement or the fact that the Investors have made or propose to make an investment in the Company, except for the Company’s disclosure in
the Registration Statement, as may be required by law, or with the prior written consent of the other parties. Each party will provide reasonable advance notice to the other parties prior to making any disclosure of this Agreement or the terms
hereof in any filings made with the SEC, and will provide the other parties with reasonable opportunity to review and comment on such proposed disclosures. Notwithstanding the foregoing, the parties may use the other parties’ current logo or
logos in connection with describing their portfolio or this investment on their webpages and in their promotional materials. 
 6.2
Survival of Representations and Warranties. The representations and warranties of the Company and the Investors contained in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement and the Closing, and
shall in no way be affected by any investigation of the subject matter thereof made by or on behalf of the Investors or the Company. 
 6.3
Governing Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware (without reference to the conflicts of law provisions thereof). 

6.4 Counterparts; Facsimile Signatures. This Agreement may be executed in two or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. This Agreement may be executed and delivered by facsimile, or by email in portable document format (.pdf) and upon such delivery of the signature page by such method
will be deemed to have the same effect as if the original signature had been delivered to the other parties. 
 6.5 Headings;
Interpretation. In this Agreement, (a) the meaning of defined terms shall be equally applicable to both the singular and plural forms of the terms defined, (b) the captions and headings are used only for convenience and are not to be
considered in construing or interpreting this Agreement and (c) the words “including,” “includes” and “include” shall be deemed to be followed by the words “without limitation.” All references in this
Agreement to sections, paragraphs, exhibits and schedules shall, unless otherwise provided, refer to sections and paragraphs hereof and exhibits and schedules attached hereto, all of which exhibits and schedules are incorporated herein by this
reference. 
 6.6 Notices. All notices which are required or permitted hereunder shall be in writing and sufficient if delivered
personally, sent by facsimile or email (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return
receipt requested, addressed as follows: 
 If to the Company, to: 

LegalZoom.com, Inc. 
 101 North
Brand Boulevard, 11th Floor 
 Glendale, California 91203 

Attention: Nicole Miller, General Counsel 

Email: nmiller@legalzoom.com 

With a copy to (which shall not constitute notice): 

Cooley LLP 
 1333 2nd Street 

Santa Monica, CA 90401 

Attention: C. Thomas Hopkins 

Email: thopkins@cooley.com 

  
 6 

 If to any Investor, to: 

Technology Crossover Ventures 

250 Middlefield Road 
 Menlo Park,
CA 94025 
 Attention: General Counsel 

Email: legal@tcv.com 

With a copy to (which shall not constitute notice): 

Weil, Gotshal & Manges LLP 

201 Redwood Shores Parkway 

Redwood Shores, CA 94065 

Attention: Kyle C. Krpata 
 Email:
kyle.krpata@weil.com 
 6.7 No Finder’s Fees. The Investors agree to indemnify and to hold harmless the Company from any
liability for any commission or compensation in the nature of a finder’s or broker’s fee (and any asserted liability as a result of the performance of services of any such finder or broker) for which the Investors or any of its officers,
partners, employees, or representatives is responsible. The Company agrees to indemnify and hold harmless the Investors from any liability for any commission or compensation in the nature of a finder’s or broker’s fee (and any asserted
liability as a result of the performance of services by any such finder or broker) for which the Company or any of its officers, employees or representatives is responsible. 

6.8 Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived
(either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the Investors. Any amendment or waiver effected in accordance with this Section 6.8
shall be binding upon each holder of any Shares at the time outstanding, each future holder of such securities and the Company. No delay or failure to require performance of any provision of this Agreement shall constitute a waiver of that provision
as to that or any other instance. No waiver granted under this Agreement as to any one provision herein shall constitute a subsequent waiver of such provision or of any other provision herein, nor shall it constitute the waiver of any performance
other than the actual performance specifically waived. 
 6.9 Severability. If any provision of this Agreement is determined by any
court or arbitrator of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such provision will be enforced to the maximum extent possible given the intent of the parties hereto. If such clause or provision cannot be so
enforced, such provision shall be stricken from this Agreement and the remainder of this Agreement shall be enforced as if such invalid, illegal or unenforceable clause or provision had (to the extent not enforceable) never been contained in this
Agreement. 
 6.10 Entire Agreement. This Agreement, together with all exhibits and schedules hereto, constitute the entire agreement
and understanding of the parties with respect to the subject matter hereof and supersede any and all prior negotiations, correspondence, agreements, understandings duties, or obligations, whether oral or written, between or among the parties hereto
with respect to the specific subject matter hereof. 
 6.11 Third Parties. Nothing in this Agreement, express or implied, is intended
to confer upon any person, other than the parties hereto and their successors and assigns, any rights or remedies under or by reason of this Agreement. 

  
 7 

 6.12 Assignment. Until the date that is two days prior to the Closing, each Investor
may assign, in its sole discretion, any or all of its rights and interests under this Agreement to one or more of its affiliates. Any assignment or reallocation of Shares shall be set forth on the updated Schedule A delivered to the Company
pursuant to Section 1.1. 
 6.13 Expenses. The Company and each Investor will each bear its own expenses in
connection with the preparation, execution and delivery of this Agreement and the consummation of the Financing. 
 6.14 Further
Assurances. The parties agree to execute such further documents and instruments and to take such further actions as may be reasonably necessary to carry out the purposes and intent of this Agreement. 

6.15 Termination. This Agreement shall automatically terminate upon the earliest to occur, if any, of: (a) either the Company, on
the one hand, or the Underwriters, on the other hand, advising the other in writing, prior to the execution of the Underwriting Agreement, that they have determined not to proceed with the IPO, (b) termination of the Underwriting Agreement
(other than the provisions thereof which survive termination) prior to the sale of any of the Common Stock to the Underwriters in the IPO, (c) the Registration Statement is withdrawn, (d) the written consent of each of the Company and the
Investors or (e) September 30, 2021, in the event that the Underwriting Agreement has not been executed by such date; provided, that the Company may, in its sole discretion, by written notice to the Investors prior to September 30,
2021, extend such date for a period of up to three additional months. 
 6.16 Waiver of Conflicts. The Investors acknowledge that
Cooley LLP (“Cooley”), counsel to the Company, may have performed and may now or in the future perform legal services for the Investors or their affiliates in matters unrelated to the transactions described in this Agreement.
Accordingly, each party to this Agreement hereby (a) acknowledges that they have had an opportunity to ask for and have obtained information relevant to this disclosure, (b) acknowledges that Cooley represents only the Company in
connection with this Agreement and the transactions contemplated hereby, and not the Investors or any stockholder, director or employee of the Investors and (c) gives its informed consent to Cooley’s representation of the Company in
connection with this Agreement and the transactions contemplated hereby. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 8 

 The parties hereto have executed this Agreement of the date first written above. 

 

			
	COMPANY:
	
	LegalZoom.com, Inc.
		
	By:	 	 /s/ Dan Wernikoff

		 	Dan Wernikoff
		 	Chief Executive Officer

 COMMON STOCK PURCHASE AGREEMENT 

 The parties hereto have executed this Agreement of the date first written above. 

 

									
	INVESTORS:	 		 		 	
			
	TCV IX, L.P.	 		 	TCV IX (A), OPPORTUNITIES L.P.
	a Cayman Islands exempted limited partnership, acting by its general partner	 		 	a Cayman Islands exempted limited partnership, acting by its general partner
			
	Technology Crossover Management IX, L.P.	 		 	Technology Crossover Management IX, L.P.
	a Cayman Islands exempted limited partnership, acting by its general partner	 		 	a Cayman Islands exempted limited partnership, acting by its general partner
			
	Technology Crossover Management IX, Ltd.	 		 	Technology Crossover Management IX, Ltd.
	a Cayman Islands exempted company	 		 	a Cayman Islands exempted company
					
	By:	 	 /s/ Frederic D. Fenton
	 		 	By:	 	 /s/ Frederic D. Fenton

	Name: Frederic D. Fenton	 		 	Name: Frederic D. Fenton
	Title: Authorized Signatory	 		 	Title: Authorized Signatory
			
	TCV IX (B), L.P.	 		 	TCV MEMBER FUND, L.P.
	a Cayman Islands exempted limited partnership, acting by its general partner	 		 	a Cayman Islands exempted limited partnership, acting by its general partner
			
	Technology Crossover Management IX, L.P.	 		 	Technology Crossover Management IX, Ltd.
	a Cayman Islands exempted limited partnership, acting by its general partner	 		 	a Cayman Islands exempted company,
				
	Technology Crossover Management IX, Ltd.	 		 	By:	 	 /s/ Frederic D. Fenton

	a Cayman Islands exempted company	 		 	Name: Frederic D. Fenton
		 		 		 	Title: Authorized Signatory
	By:	 	 /s/ Frederic D. Fenton
	 		 		 	
		 	Name: Frederic D. Fenton	 		 		 	
		 	Title: Authorized Signatory	 		 		 	

 COMMON STOCK PURCHASE AGREEMENT 

 SCHEDULE A 

Schedule of Investors 
  

					
	 Name of Investor
	  	Purchase Price Paid by Investor	 
	 TCV IX, L.P.
	  	$	63,709,092.00	 
	 TCV IX (A) Opportunities, L.P.
	  	$	17,976,363.00	 
	 TCV IX (B), L.P.
	  	$	3,402,545.00	 
	 TCV Member Fund, L.P.
	  	$	4,912,000.00	 
		  	  
	  
	 
	 Total:
	  	$	90,000,000

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]